Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients 12 ≤ age ≤ 60 upon study consent;~* Diagnosis of Alport syndrome by genetic testing (documented mutation in a gene associated with Alport syndrome, including COL4A3, COL4A4, or COL4A5) or histologic assessment using electron microscopy;~* Screening eGFR ≥ 30 and ≤ 90 mL/min/1.73 m2. The two eGFR values collected at Screen A and Screen B visits used to determine eligibility must have a percent difference ≤ 25%;~* Albumin to creatinine ratio (ACR) ≤ 3500 mg/g at Screen B visit;~* If receiving an angiotensin-converting enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB), the medications must remain the same for at least 6 weeks prior to the Screen A visit and during Screening. The dosage of ACE inhibitor and/or ARB must also be stable for 2 weeks prior to the Screen A visit and remain the same through Day 1 (i.e., no change in dosage or medication). Patients not taking an ACE inhibitor and/or ARB because of a medical contraindication must have discontinued treatment at least 8 weeks prior to the Screen A visit;~* Adequate bone marrow reserve and organ function at the Screen A visit~* Able to swallow capsules;~* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;~Exclusion Criteria:~* Prior exposure to bardoxolone methyl;~* Ongoing chronic hemodialysis or peritoneal dialysis therapy;~* Renal transplant recipient;~* B-type natriuretic peptide (BNP) level \> 200 pg/mL at Screen A visit;~* Uncontrolled diabetes (HbA1c \> 11.0%) at Screen A visit;~* Acute dialysis or acute kidney injury within 12 weeks prior to Screen A visit or during Screening;~* Serum albumin \< 3 g/dL at Screen A visit;~* History of clinically significant left-sided heart disease and/or clinically significant cardiac disease, including but not limited to any of the following:~* Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (BP) \> 160 mm Hg or sitting diastolic BP \> 100 mm Hg at Screen A visit after a period of rest;~* Systolic BP \< 90 mm Hg at Screen A visit after a period of rest;~* History of malignancy within 5 years prior to Screen A visit, with the exception of localized skin or cervical carcinomas;~* Systemic immunosuppression for more than 2 weeks, cumulatively, within the 12 weeks prior to randomization or anticipated need for immunosuppression during the study;~* Untreated or uncontrolled active bacterial, fungal, or viral infection;~* Participation in other interventional clinical studies within 30 days prior to Day 1;~* Unwilling to practice acceptable methods of birth control (both males who have partners of child-bearing potential and females of childbearing potential) during Screening, while taking study drug, and for at least 30 days after the last dose of study drug is ingested;~* Women who are pregnant or breastfeeding;~* Known hypersensitivity to any component of the study drug

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Phase 2 Bardoxolone Methyl (Type: EXPERIMENTAL): Patients in the Phase 2 cohort will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR \> 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR \>300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
- Phase 3 Bardoxolone Methyl (Type: ACTIVE_COMPARATOR): Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR \> 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR \>300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
- Phase 3 Placebo (Type: PLACEBO_COMPARATOR): Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.

Based on this trial design, predict the completion outcome and termination type (if applicable).